Published in Mol Neurobiol on March 07, 2015
Insulin resistance in Alzheimer's disease. Transl Res (2016) 0.75
Pterostilbene ameliorates intracerebroventricular streptozotocin induced memory decline in rats. Cogn Neurodyn (2016) 0.75
Long-term treatment with intranasal insulin ameliorates cognitive impairment, tau hyperphosphorylation, and microglial activation in a streptozotocin-induced Alzheimer's rat model. Sci Rep (2017) 0.75
Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin. PLoS One (2017) 0.75
Embelin Attenuates Intracerebroventricular Streptozotocin-Induced Behavioral, Biochemical, and Neurochemical Abnormalities in Rats. Mol Neurobiol (2016) 0.75
Rat brain glucose transporter-2, insulin receptor and glial expression are acute targets of intracerebroventricular streptozotocin: risk factors for sporadic Alzheimer's disease? J Neural Transm (Vienna) (2017) 0.75
The effects of lipoic acid on redox status in brain regions and systemic circulation in streptozotocin-induced sporadic Alzheimer's disease model. Metab Brain Dis (2017) 0.75
Alzheimer's disease: the amyloid cascade hypothesis. Science (1992) 13.80
Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature (1995) 9.39
A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med (2012) 8.04
The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia (2007) 4.55
Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res (2005) 3.96
Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? J Alzheimers Dis (2005) 3.78
Diabetogenic action of streptozotocin: relationship of dose to metabolic response. J Clin Invest (1969) 3.16
Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ ) deposition. Proc Natl Acad Sci U S A (2010) 2.80
Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A (2004) 2.54
Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J Nucl Med (2006) 2.17
Hyperglycemia-induced oxidative stress in diabetic complications. Histochem Cell Biol (2004) 1.98
Altered cerebral energy metabolism in Alzheimer's disease: a PET study. J Nucl Med (1994) 1.90
Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging (2007) 1.90
Hypothalamic tanycytes: a key component of brain-endocrine interaction. Int Rev Cytol (2005) 1.87
Poly(ADP-ribose) polymerase gene disruption conferred mice resistant to streptozotocin-induced diabetes. Proc Natl Acad Sci U S A (1999) 1.85
Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis (2006) 1.82
Insulin receptor synthesis and turnover in differentiating 3T3-L1 preadipocytes. Proc Natl Acad Sci U S A (1980) 1.82
Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. J Neurosci (2005) 1.76
Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. Proc Natl Acad Sci U S A (1999) 1.71
Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimers Dis (2006) 1.65
Free fatty acids and skeletal muscle insulin resistance. Curr Opin Lipidol (2008) 1.64
Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease. Ageing Res Rev (2012) 1.57
Of mice and men: bridging the translational disconnect in CNS drug discovery. CNS Drugs (2009) 1.56
Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes (2000) 1.48
Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int (2002) 1.48
'Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci (2010) 1.47
Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies. Alzheimers Res Ther (2011) 1.43
Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem (1994) 1.40
Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem (2007) 1.37
Decreased autophosphorylation of the insulin receptor-kinase in streptozotocin-diabetic rats. J Biol Chem (1984) 1.34
Concentrations of insulin and insulin receptors in the brain are independent of peripheral insulin levels. Studies of obese and streptozotocin-treated rodents. J Clin Invest (1979) 1.34
Hypothalamic ependymal-glial cells express the glucose transporter GLUT2, a protein involved in glucose sensing. J Neurochem (2003) 1.28
The genetics of Alzheimer's disease. Prog Mol Biol Transl Sci (2012) 1.28
Hepatic glucose sensing is required to preserve β cell glucose competence. J Clin Invest (2013) 1.27
Brain glucose sensing and neural regulation of insulin and glucagon secretion. Diabetes Obes Metab (2011) 1.26
Insulin in the brain: there and back again. Pharmacol Ther (2012) 1.25
Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway. J Neurochem (2006) 1.23
Third ventricular alloxan reversibly impairs glucose counterregulatory responses. Diabetes (2004) 1.22
Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease. Am J Pathol (2009) 1.21
Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem Pharmacol (2013) 1.21
APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis. Brain Struct Funct (2009) 1.20
Studies on streptozotocin diabetes. Diabetes (1976) 1.16
Drug transport in brain via the cerebrospinal fluid. Fluids Barriers CNS (2011) 1.15
Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease. J Alzheimers Dis (2009) 1.15
Shock, inflammation and PARP. Pharmacol Res (2005) 1.12
Enzymic and cerebral metabolic effects of 2-deoxy-D-glucose. J Neurochem (1973) 1.10
Reduced hippocampal neurogenesis and number of hilar neurones in streptozotocin-induced diabetic mice: reversion by antidepressant treatment. Eur J Neurosci (2006) 1.09
Involvement of astroglial ceramide in palmitic acid-induced Alzheimer-like changes in primary neurons. Eur J Neurosci (2007) 1.06
Tanycyte-like cells form a blood-cerebrospinal fluid barrier in the circumventricular organs of the mouse brain. J Comp Neurol (2013) 1.06
The role of amyloid β in the pathogenesis of Alzheimer's disease. J Clin Pathol (2013) 1.03
Glial activation and post-synaptic neurotoxicity: the key events in Streptozotocin (ICV) induced memory impairment in rats. Pharmacol Biochem Behav (2013) 1.03
Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease? Ageing Res Rev (2011) 1.03
Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer (2010) 1.02
Changes in tyrosine phosphorylation of insulin receptors and a 170,000 molecular weight nonreceptor protein in vivo in skeletal muscle of streptozotocin-induced diabetic rats: effects of insulin and glucose. Endocrinology (1992) 0.99
The effect of insulin deficiency on tau and neurofilament in the insulin knockout mouse. Biochem Biophys Res Commun (2005) 0.98
Distribution and anatomical localization of the glucose transporter 2 (GLUT2) in the adult rat brain--an immunohistochemical study. J Chem Neuroanat (2004) 0.98
What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research. J Neural Transm (Vienna) (2012) 0.97
Within-patient correspondence of amyloid-β and intrinsic network connectivity in Alzheimer's disease. Brain (2014) 0.96
Is insulin resistant brain state a central feature of the metabolic-cognitive syndrome? J Alzheimers Dis (2010) 0.96
Chronic treatment with tocotrienol, an isoform of vitamin E, prevents intracerebroventricular streptozotocin-induced cognitive impairment and oxidative-nitrosative stress in rats. Pharmacol Biochem Behav (2009) 0.95
Fatty acid uptake and incorporation in brain: studies with the perfusion model. J Mol Neurosci (2001) 0.95
Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats. Int J Dev Neurosci (1994) 0.95
Glial glucokinase expression in adult and post-natal development of the hypothalamic region. ASN Neuro (2010) 0.94
Inhibition of the neuronal insulin receptor. An in vivo model for sporadic Alzheimer disease? Ann N Y Acad Sci (2000) 0.94
Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer's disease: a long-term follow up study. J Neural Transm (Vienna) (2011) 0.94
Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis. Expert Rev Neurother (2010) 0.93
Diabetes mellitus concomitantly facilitates the induction of long-term depression and inhibits that of long-term potentiation in hippocampus. Eur J Neurosci (2005) 0.92
Desensitization of brain insulin receptor. Effect on glucose/energy and related metabolism. J Neural Transm Suppl (1994) 0.92
A non-transgenic mouse model (icv-STZ mouse) of Alzheimer's disease: similarities to and differences from the transgenic model (3xTg-AD mouse). Mol Neurobiol (2012) 0.91
Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases. J Neural Transm Park Dis Dement Sect (1991) 0.91
What causes alzheimer's disease? Folia Neuropathol (2013) 0.90
Local action of the diabetogenic drug, streptozotocin, on glucose and energy metabolism in rat brain cortex. Neurosci Lett (1991) 0.90
Intracerebroventricular injection of streptozotocin causes neurotoxicity to myelin that contributes to spatial memory deficits in rats. Exp Neurol (2003) 0.90
Intracerebroventricular administration of drugs. Pharmacotherapy (2009) 0.90
Type 3 diabetes is sporadic Alzheimer׳s disease: mini-review. Eur Neuropsychopharmacol (2014) 0.90
Metabolic changes in rat brain following intracerebroventricular injections of streptozotocin: a model of sporadic Alzheimer's disease. Acta Neurochir Suppl (2010) 0.89
Modeling sporadic Alzheimer's disease: the insulin resistant brain state generates multiple long-term morphobiological abnormalities including hyperphosphorylated tau protein and amyloid-beta. J Alzheimers Dis (2009) 0.88
ICV STZ induced impairment in memory and neuronal mitochondrial function: A protective role of nicotinic receptor. Behav Brain Res (2011) 0.86
Gliotransmission and brain glucose sensing: critical role of endozepines. Diabetes (2012) 0.86
Developmental regulation of insulin in the mammalian central nervous system. Brain Res (1992) 0.85
Alzheimer's disease and amyloid: culprit or coincidence? Int Rev Neurobiol (2012) 0.85
Streptozotocin increases free fatty acids and decreases phospholipids in rat brain. J Neural Transm (Vienna) (1998) 0.84
Early appearance of in vivo insulin resistance in adult streptozotocin-injected rats. Diabete Metab (1990) 0.84
Alzheimer's disease pathologic cascades: who comes first, what drives what. Neurotox Res (2011) 0.83
In vivo cross-sectional characterization of cerebral alterations induced by intracerebroventricular administration of streptozotocin. PLoS One (2012) 0.82
Mitochondrial abnormalities in a streptozotocin-induced rat model of sporadic Alzheimer's disease. Curr Alzheimer Res (2013) 0.81
Intraventricular alloxan eliminates feeding elicited by 2-deoxyglucose. Science (1978) 0.80
Altered energy metabolism in Alzheimer's disease. J Neurol Sci (1996) 0.80
Streptozotocin and alloxan produce alterations in rat brain monoamines independently of pancreatic beta cells destruction. Life Sci (1990) 0.79
Intracerebroventricular streptozotocin exacerbates Alzheimer-like changes of 3xTg-AD mice. Mol Neurobiol (2013) 0.79
Glucoprivic feeding is impaired by lateral or fourth ventricular alloxan injection. Am J Physiol (1982) 0.79
Stimulation of glycolytic key enzymes in cerebral cortex by insulin. Neuroreport (1993) 0.78
Palmitate induces transcriptional regulation of BACE1 and presenilin by STAT3 in neurons mediated by astrocytes. Exp Neurol (2013) 0.78
Antioxidant capacity in rat brain after intracerebroventricular treatment with streptozotocin and alloxan--a preliminary study. Neurotox Res (2008) 0.78
Early and late neurodegeneration and memory disruption after intracerebroventricular streptozotocin. Physiol Behav (2012) 0.78
2-deoxyglucose induces beta-APP overexpression, tau hyperphosphorylation and expansion of the trans-part of the Golgi complex in rat cerebral cortex. Acta Neurobiol Exp (Wars) (2004) 0.78
Brain enzyme activities after intracerebroventricular injection of streptozotocin in rats receiving acetyl-L-carnitine. Eur J Pharmacol (1995) 0.77
Metabolic derangements mediate cognitive impairment and Alzheimer's disease: role of peripheral insulin-resistance diseases. Panminerva Med (2012) 0.77
Insulin-sensitive glucoreceptors in rat preoptic area that regulate FFA mobilization. Am J Physiol (1986) 0.77
Expansion of the Golgi apparatus in rat cerebral cortex following intracerebroventricular injections of streptozotocin. Acta Neurobiol Exp (Wars) (2004) 0.76